Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Third FSME-IMMUN Vaccination in Children
NCT00161889Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2002
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of FSME-IMMUN in tick-borne encephalitis (TBE), sponsored by Pfizer. Started Feb 2002; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00161889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161889.